Potent HCV NS3 Protease Inhibition by a Water-Soluble Phyllanthin Congener

被引:3
作者
Reddy, Uma B. [2 ]
Tandon, Himani [1 ]
Pradhan, Manoj K. [4 ]
Adhikesavan, Harikrishnan [4 ]
Srinivasan, Narayanaswamy [1 ]
Das, Saumitra [2 ,3 ]
Jayaraman, Narayanaswamy [4 ]
机构
[1] Indian Inst Sci, Mol Biophys Unit, Bangalore 560012, Karnataka, India
[2] Indian Inst Sci, Microbiol & Cell Biol, Bangalore 560012, Karnataka, India
[3] Natl Inst Biomed Genom, Kalyani 741251, W Bengal, India
[4] Indian Inst Sci, Dept Organ Chem, Bangalore 560012, Karnataka, India
来源
ACS OMEGA | 2020年 / 5卷 / 20期
关键词
HEPATITIS-C-VIRUS; CRYSTAL-STRUCTURES; SERINE-PROTEASE; RNA REPLICATION; AMARUS; PROTEINASE; RESISTANCE; CLEAVAGE; FITNESS; ASSAY;
D O I
10.1021/acsomega.0c00786
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
NS3/4A protease of hepatitis C virus (HCV) plays an important role in viral RNA replication. A 1,4-diphenylbutanedicarboxylic acid derivative, namely, phyllanthin, extracted from the leaf of a herbal plant, Phyllanthus amarus, inhibits HCV NS3/4A protease and replication activities. However, the reduced aqueous solubility, high toxicity, and poor oral bioavailability are major impediments with phyllanthin. We herein present a design approach to generate phyllanthin congeners in order to potentiate inhibition activity against protease. The phyllanthin congeners were synthesized by chemical methods and subjected to systematic biological studies. One of the congeners, annotated as D8, is identified as a novel and potent inhibitor of the HCV-NS3/4Aprotease activity in vitro and the viral RNA replication in cell culture. Structural analysis using the computational-based docking approach demonstrated important noncovalent interactions between D8 and the catalytic residues of the viral protease. Furthermore, D8 was found to be significantly nontoxic in cell culture. More importantly, oral administration of D8 in BALB/c mice proved its better tolerability and bioavailability, as compared to native phyllanthin. Taken together, this study reveals a promising candidate for developing anti-HCV therapeutics to control HCV-induced liver diseases.
引用
收藏
页码:11553 / 11562
页数:10
相关论文
共 50 条
  • [41] ASUNAPREVIR HCV Serine Protease NS3 Inhibitor Treatment of Hepatitis C Virus
    Reviriego, C.
    [J]. DRUGS OF THE FUTURE, 2012, 37 (04) : 247 - 254
  • [42] The NS4A Cofactor Dependent Enhancement of HCV NS3 Protease Activity Correlates with a 4D Geometrical Measure of the Catalytic Triad Region
    Hamad, Hamzah A.
    Thurston, Jeremy
    Teague, Thomas
    Ackad, Edward
    Yousef, Mohammad S.
    [J]. PLOS ONE, 2016, 11 (12):
  • [43] Suppression of hepatitis C virus by the flavonoid quercetin is mediated by inhibition of NS3 protease activity
    Bachmetov, L.
    Gal-Tanamy, M.
    Shapira, A.
    Vorobeychik, M.
    Giterman-Galam, T.
    Sathiyamoorthy, P.
    Golan-Goldhirsh, A.
    Benhar, I.
    Tur-Kaspa, R.
    Zemel, R.
    [J]. JOURNAL OF VIRAL HEPATITIS, 2012, 19 (02) : E81 - E88
  • [44] Dynamic change in the NS3 protease domain in HIV/HCV-coinfected patients naive to anti-HCV protease inhibitors
    Bagaglio, Sabrina
    Messina, Emanuela
    Hasson, Hamid
    Merli, Marco
    Andolina, Andrea
    Lazzarin, Adriano
    Uberti-Foppa, Caterina
    Morsica, Giulia
    [J]. NEW MICROBIOLOGICA, 2017, 40 (01) : 53 - 55
  • [45] The Electronic and Quantitative Structure Activity Relationship Properties of Modified Telaprevir Compounds as HCV NS3 Protease Inhibitors
    Saleh, Noha A.
    Elfiky, Abdo A.
    Ezat, Ahmed A.
    Elshemey, Wael M.
    Ibrahim, Medhat
    [J]. JOURNAL OF COMPUTATIONAL AND THEORETICAL NANOSCIENCE, 2014, 11 (02) : 544 - 548
  • [46] Crowded environment affects the activity and inhibition of the NS3/4A protease
    Popielec, Agnieszka
    Ostrowska, Natalia
    Wojciechowska, Monika
    Feig, Michael
    Trylska, Joanna
    [J]. BIOCHIMIE, 2020, 176 : 169 - 180
  • [47] Compensatory substitutions in the HCV NS3/4A protease cleavage sites are not observed in patients treated unsuccessfully with telaprevir combination treatment
    Sullivan, James C.
    Zhang, Eileen Z.
    Bartels, Doug J.
    Tigges, Ann
    Dorrian, Jennifer L.
    Kwong, Ann D.
    Kieffer, Tara L.
    [J]. VIROLOGY JOURNAL, 2012, 9
  • [48] Genetic background for development of resistance mutations within the HCV NS3 protease-helicase in direct acting antiviral naive patients
    Grammatikos, Georgios
    Jabara, Cassandra B.
    Ahmad, Monazza Q.
    Herrmann, Eva
    Zeuzem, Stefan
    Welsch, Christoph
    [J]. ANTIVIRAL THERAPY, 2014, 19 (05) : 455 - 461
  • [49] In Silico Identification and Evaluation of Leads for the Simultaneous Inhibition of Protease and Helicase Activities of HCV NS3/4A Protease Using Complex Based Pharmacophore Mapping and Virtual Screening
    Wadood, Abdul
    Riaz, Muhammad
    Uddin, Reaz
    ul-Haq, Zaheer
    [J]. PLOS ONE, 2014, 9 (02):
  • [50] Classification Models of HCV NS3 Protease Inhibitors Based on Support Vector Machine (SVM)
    Wang, Maolin
    Xuan, Shouyi
    Yan, Aixia
    Yu, Changyuan
    [J]. COMBINATORIAL CHEMISTRY & HIGH THROUGHPUT SCREENING, 2015, 18 (01) : 24 - 32